6.4.5.1.2. salvage radiotherapy combined androgen deprivation therapy (ctxcn0, without pet/ct). data rtog 9601 suggest css os benefit adding two years bicalutamide (150 mg o.d.) srt . according getug-afu 16 also 6-months treatment lhrh-analogue significantly improve 10-year bcr, biochemical pfs and, modestly, mfs. however, srt combined either goserelin placebo showed similar dss os rates . addition, pollack et al., reported results randomised 3-arm phase iii trial (nrg oncology/rtog 0534 spport) adding six months treatment lhrh-analogue srt prostate bed (pbrt) (group 2) compared pbrt alone (group 1) former combination pbrt-rt pelvic ln rt (plnrt) (group 3) . primary endpoint freedom progression (ffp) five years. however, using phoenix-definition biochemical progression (nadir + 2 ng/ml used definitive rt), criterion nadir + 0.2, used commonly (but without clear evidence) resulted later diagnosis progression spport trial. median follow-up 8.2 years surviving patients ffp increased significant group 3 (87.4%) compared group 2 (81.3%) (p = 0.0027) group 1 (70.9%) (p < 0.0001) difference group 2 group 1 also significant (p < 0.0001). distant metastasis incidence rates lowest group 3 lower compared group 1 (pbrt only, hr: 0.52) similar rate pca deaths (hr: 0.51). significant difference seen os. significantly higher risk acute- late side effects group 3. therefore, role additional plnrt remains unclear proven rcts including psma pet-ct . table 6.4.5 provides overview three rcts. rcts support adding adt srt. however, interpreting data kept mind rtog 9601 used outdated radiation dosages (< 66 gy) technique. question respect patient risk profile, whether offer combination treatment not, optimal combination (lhrh bicalutamide) remains, yet, unsolved. eau bcr risk classification may offer guidance respect . one rcts reports improved os (rtog 96-01) (getug-afu 16) improved mfs due methodological discrepancies also related follow-up risk, is, yet, evident patients receive adt, type adt, long. men high risk progression (e.g., psa ≥ 0.7 ng/ml gs ≥ 8) may benefit srt combined two years adt; lower risk (e.g., psa < 0.7 ng/ml gs = 8) srt combined six months adt may sufficient. men low-risk profile (psa < 0.5 ng/ml gs < 8) may receive srt alone. sub-analysis men psa 0.61 1.5 (n = 253) os benefit associated antiandrogen assignment (hr: 0.61, 95% ci: 0.39–0.94) . receiving early srt (psa 0.6 ng/ml, n = 389), improvement os (hr: 1.16, 95% ci: 0.79–1.70), increased other-cause mortality (sub-distribution hr: 1.94, 95% ci: 1.17–3.20, p = 0.01) increased odds late grades 3–5 cardiac neurologic toxic side effects (or: 3.57, 95% ci: 1.09–15.97, p = 0.05). results suggest pre-srt psa level may prognostic biomarker outcomes anti-androgen treatment srt. patients receiving late srt (psa > 0.6 ng/ml), ht associated improved outcomes. men receiving early srt (psa < 0.6 ng/ml), long-term anti-androgen treatment associated improved os . sr addressing benefit combining ht srt suggested risk stratification patients based pre-srt psa (< 0.5, 0.6–1, > 1 ng/ml), margin status isup grade framework individualise treatment . table 6.4.5: randomised controlled trials comparing salvage radiotherapy combined androgen deprivation therapy vs. salvage radiotherapy alone studynrisk groupsmedian fu (mo)regimenoutcomegetug-afu 16 2019 369 rt + adt374 rtisup grade< 2/3 89%isup grade> 4 11%cn011266 gy pbrt + 6 mo. lhrh analogue66 gy bprt10-yr.pfs: rt + adt, 64%pfs: rt, 49%p < 0.0001mfs: rt + adt, 75%mfs: rt, 69%p = 0.034rtog 96012017 384 rt + adt376 rtpt2 r1, pt3 cn015664.8 gy pbrt + bicalutamide 24 mo.64.8 gy pbrt + placebo12-yr.cumulative dmrt + adt: 14%rt + placebo: 23%p = 0.005osrt + adt: 76%rt + placebo: 71%p = 0.04dsmrt + adt: 5.8%rt + placebo: 13.4%p < 0.001nrg oncology/rtog 0534 spport 564 pbrt + alone578 pbrt + adt574 pbrt +plnrt + adtpt2 pt3isup < 5pre srtpsa: 0.1-2.0survivors:8.2 years64.8–70.2 gy pbrt64.8–70.2 gy pbrt +6 mo. lhrh analogue64.8–70.2 gy pbrt + 45 gy plnrt +6 mo. lhrh analogue5-yr. ffp (primary endpoint)70.9% group 181.3% group 287.4% group 3comparisons :g 3 vs. g 1:p < 0.0001g 2 vs. g 1p < 0.0001g 3 vs. g 2p < 0.0027 adt = androgen deprivation therapy; dm = distant metastasis; dsm = disease specific mortality; pfs = progression free survival; ffp = freedom progression; fu = follow-up; lhrh = luteinising hormone-releasing hormone; mfs = metastasis-free survival; os = overall survival; pfs = progression-free survival; mo = months; n = number patients; rt = radiotherapy; yr = year, pbrt = prostate bed radiotherapy; plnrt = pelvic lymph node radiotherapy.